New approaches to the treatment of nephropathy in diabetes

Bibliography

• Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782-7
   PubMed Web of Science ®Google Scholar
• Federation ID. IDF Diabetes Atlas. 4th edition. International Diabetes Federation. Brussels, Belgium; 2009
   Google Scholar
• Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care 2003;26:917-32
   PubMed Web of Science ®Google Scholar
• Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999;341:1127-33
   PubMed Web of Science ®Google Scholar
• U. S. Renal Data System, USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD, USA; 2004
   Google Scholar
• Groop PH, Thomas MC, Moran JL, The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 2009;58:1651-8
   PubMed Web of Science ®Google Scholar
• Stephenson JM, Kenny S, Stevens LK, Proteinuria and mortality in diabetes: the WHO Multinational Study of Vascular Disease in Diabetes. Diabet Med 1995;12:149-55
   PubMed Web of Science ®Google Scholar
• Adler AI, Stevens RJ, Manley SE, Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225-32
   PubMed Web of Science ®Google Scholar
• Gaede P, Vedel P, Larsen N, Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93
   PubMed Web of Science ®Google Scholar
• Cicoira M, Zanolla L, Rossi A, Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol 2001;37:1808-12
   PubMed Web of Science ®Google Scholar
• Staessen J, Lijnen P, Fagard R, Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981;91:457-65
   PubMed Web of Science ®Google Scholar
• Lee AF, MacFadyen RJ, Struthers AD. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. Eur J Heart Fail 1999;1:401-6
   PubMed Web of Science ®Google Scholar
• Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007;3:486-92
   PubMedGoogle Scholar
• Schjoedt KJ, Andersen S, Rossing P, Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004;47:1936-9
   PubMed Web of Science ®Google Scholar
• Horita Y, Taura K, Taguchi T, Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy. Nephrology (Carlton) 2006;11:462-6
   PubMed Web of Science ®Google Scholar
• Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003;41:64-8
   PubMed Web of Science ®Google Scholar
• Tang WH, Vagelos RH, Yee YG, Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 2002;39:70-8
   PubMed Web of Science ®Google Scholar
• Pitt B. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 1995;9:145-9
   PubMed Web of Science ®Google Scholar
• Struthers AD. The clinical implications of aldosterone escape in congestive heart failure. Eur J Heart Fail 2004;6:539-45
   PubMed Web of Science ®Google Scholar
• Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 2002;39:E1-8
   PubMed Web of Science ®Google Scholar
• Parving HH, Persson F, Lewis JB, Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-46
   PubMed Web of Science ®Google Scholar
• Persson F, Rossing P, Reinhard H, Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 2009;32:1873-9
   PubMed Web of Science ®Google Scholar
• Parving HH, Brenner BM, McMurray JJ, Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009;24:1663-71
   PubMed Web of Science ®Google Scholar
• MacFadyen RJ, Lee AF, Morton JJ, How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 1999;82:57-61
   PubMed Web of Science ®Google Scholar
• Urata H, Kinoshita A, Misono KS, Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990;265:22348-57
   PubMed Web of Science ®Google Scholar
• Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003;14:1738-47
   PubMed Web of Science ®Google Scholar
• Ritz E. Chymase: a potential culprit in diabetic nephropathy? J Am Soc Nephrol 2003;14:1952-4
   PubMed Web of Science ®Google Scholar
• Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007;59:251-87
   PubMed Web of Science ®Google Scholar
• Maeda Y, Inoguchi T, Takei R, Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters. Am J Physiol Renal Physiol 2010;299:1328-38
   Google Scholar
• Tikellis C, Johnston CI, Forbes JM, Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 2003;41:392-7
   PubMed Web of Science ®Google Scholar
• Lely AT, Hamming I, van Goor H, Navis GJ. Renal ACE2 expression in human kidney disease. J Pathol 2004;204:587-93
   PubMed Web of Science ®Google Scholar
• Oudit GY, Liu GC, Zhong J, Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes 2010;59:529-38
   PubMed Web of Science ®Google Scholar
• Rossing K, Schjoedt KJ, Smidt UM, Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 2005;28:2106-12
   PubMed Web of Science ®Google Scholar
• Mehdi UF, Adams-Huet B, Raskin P, Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009;20:2641-50
   PubMed Web of Science ®Google Scholar
• Epstein M, Williams GH, Weinberger M, Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006;1:940-51
   PubMed Web of Science ®Google Scholar
• Smulders YM, van Eeden AE, Stehouwer CD, Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus? Eur J Clin Invest 1997;27:997-1002
   PubMed Web of Science ®Google Scholar
• Nagai T, Tomizawa T, Nakajima K, Mori M. Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients. J Atheroscler Thromb 2000;7:91-6
   PubMedGoogle Scholar
• Park CW, Zhang Y, Zhang X, PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int 2006;69:1511-17
   PubMed Web of Science ®Google Scholar
• Ren S, Xin C, Beck KF, PPARalpha activation upregulates nephrin expression in human embryonic kidney epithelial cells and podocytes by a dual mechanism. Biochem Biophys Res Commun 2005;338:1818-24
   PubMed Web of Science ®Google Scholar
• Zhao X, Li LY. PPAR-alpha agonist fenofibrate induces renal CYP enzymes and reduces blood pressure and glomerular hypertrophy in Zucker diabetic fatty rats. Am J Nephrol 2008;28:598-606
   PubMed Web of Science ®Google Scholar
• Gonzalez FJ. Recent update on the PPAR alpha-null mouse. Biochimie 1997;79:139-44
   PubMed Web of Science ®Google Scholar
• Hattori Y, Hattori S, Kasai K. Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells. Hypertension 1999;33:943-8
   PubMed Web of Science ®Google Scholar
• Chawla A, Barak Y, Nagy L, PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001;7:48-52
   PubMed Web of Science ®Google Scholar
• Ansquer JC, Foucher C, Rattier S, Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005;45:485-93
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Elam MB, Lovato LC, Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-4
   PubMed Web of Science ®Google Scholar
• Jun M, Foote C, Lv J, Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010;362:1563-74
   Google Scholar
• Isshiki K, Haneda M, Koya D, Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 2000;49:1022-32
   PubMed Web of Science ®Google Scholar
• Ko GJ, Kang YS, Han SY, Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrol Dial Transplant 2008;23:2750-60
   PubMed Web of Science ®Google Scholar
• Gumieniczek A. Effect of the new thiazolidinedione-pioglitazone on the development of oxidative stress in liver and kidney of diabetic rabbits. Life Sci 2003;74:553-62
   PubMed Web of Science ®Google Scholar
• Gumieniczek A. Effects of pioglitazone on hyperglycemia-induced alterations in antioxidative system in tissues of alloxan-treated diabetic animals. Exp Toxicol Pathol 2005;56:321-6
   PubMed Web of Science ®Google Scholar
• Isshiki K, Haneda M, Koya D, Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 2000;49:1022-32
   PubMed Web of Science ®Google Scholar
• Fujii M, Takemura R, Yamaguchi M, Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats. Metabolism 1997;46:981-3
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Stafylas PC, Georgianos PI, Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. Am J Kidney Dis 2010;55:835-47
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010;170:1191-201
   PubMed Web of Science ®Google Scholar
• Betteridge DJ. CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone. Fundam Clin Pharmacol 2009;23:675-9
   PubMed Web of Science ®Google Scholar
• Tanaka H, Hamano T, Fujii N, The impact of diabetes mellitus on vitamin D metabolism in predialysis patients. Bone 2009;45:949-55
   PubMed Web of Science ®Google Scholar
• Rojas-Rivera J, De La Piedra C, Ramos A, The expanding spectrum of biological actions of vitamin D. Nephrol Dial Transplant 2010;25:2850-65
   PubMed Web of Science ®Google Scholar
• Li YC, Kong J, Wei M, 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002;110:229-38
   PubMed Web of Science ®Google Scholar
• Porsti IH. Expanding targets of vitamin D receptor activation: downregulation of several RAS components in the kidney. Kidney Int 2008;74:1371-3
   PubMed Web of Science ®Google Scholar
• Freundlich M, Quiroz Y, Zhang Z, Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 2008;74:1394-402
   PubMed Web of Science ®Google Scholar
• Wu-Wong JR. Potential for vitamin D receptor agonists in the treatment of cardiovascular disease. Br J Pharmacol 2009;158:395-412
   PubMed Web of Science ®Google Scholar
• Zhang Z, Sun L, Wang Y, Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 2008;73:163-71
   PubMed Web of Science ®Google Scholar
• Alborzi P, Patel NA, Peterson C, Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008;52:249-55
   PubMed Web of Science ®Google Scholar
• Agarwal R, Acharya M, Tian J, Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005;68:2823-8
   PubMed Web of Science ®Google Scholar
• Fishbane S, Chittineni H, Packman M, Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis 2009;54:647-52
   PubMed Web of Science ®Google Scholar
• de Zeeuw D, Agarwal R, Amdahl M, Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010;376:1543-51
   PubMed Web of Science ®Google Scholar
• Witham MD, Dove FJ, Dryburgh M, The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial. Diabetologia 2010;53:2112-19
   PubMed Web of Science ®Google Scholar
• Teng M, Wolf M, Lowrie E, Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-56
   PubMed Web of Science ®Google Scholar
• Tentori F, Hunt WC, Stidley CA, Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006;70:1858-65
   PubMed Web of Science ®Google Scholar
• Burns WC, Thomas MC. The molecular mediators of type 2 epithelial to mesenchymal transition (EMT) and their role in renal pathophysiology. Expert Rev Mol Med 2010;12:e17
   PubMed Web of Science ®Google Scholar
• Bhowmick NA, Ghiassi M, Aakre M, TGF-beta-induced RhoA and p160ROCK activation is involved in the inhibition of Cdc25A with resultant cell-cycle arrest. Proc Natl Acad Sci USA 2003;100:15548-53
   PubMed Web of Science ®Google Scholar
• Rodrigues-Diez R, Carvajal-Gonzalez G, Sanchez-Lopez E, Pharmacological modulation of epithelial mesenchymal transition caused by angiotensin II. Role of ROCK and MAPK pathways. Pharm Res 2008;25:2447-61
   PubMed Web of Science ®Google Scholar
• Guo X, Wang L, Chen B, ERM protein moesin is phosphorylated by advanced glycation end products and modulates endothelial permeability. Am J Physiol Heart Circ Physiol 2009;297:H238-46
   PubMed Web of Science ®Google Scholar
• Komers R, Oyama TT, Beard DR, Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure. Kidney Int 2011;79:432-42
   PubMed Web of Science ®Google Scholar
• Kolavennu V, Zeng L, Peng H, Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes 2008;57:714-23
   PubMed Web of Science ®Google Scholar
• Noma K, Oyama N, Liao JK. Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol 2006;290:C661-8
   PubMed Web of Science ®Google Scholar
• Laufs U, Marra D, Node K, Liao JK. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem 1999;274:21926-31
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 2009;54:810-19
   PubMed Web of Science ®Google Scholar
• Douglas K, O'Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 2006;145:117-24
   PubMed Web of Science ®Google Scholar
• Peng F, Wu D, Gao B, RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease. Diabetes 2008;57:1683-92
   PubMed Web of Science ®Google Scholar
• Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006;98:322-34
   PubMed Web of Science ®Google Scholar
• Soulis-Liparota T, Cooper ME, Dunlop M, Jerums G. The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia 1995;38:387-94
   PubMed Web of Science ®Google Scholar
• Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-20
   PubMed Web of Science ®Google Scholar
• Soulis-Liparota T, Cooper M, Papazoglou D, Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991;40:1328-34
   PubMed Web of Science ®Google Scholar
• Vlassara H, Striker LJ, Teichberg S, Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 1994;91:11704-8
   PubMed Web of Science ®Google Scholar
• Wendt TM, Tanji N, Guo J, RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003;162:1123-37
   PubMed Web of Science ®Google Scholar
• Morcos M, Sayed AA, Bierhaus A, Activation of tubular epithelial cells in diabetic nephropathy. Diabetes 2002;51:3532-44
   PubMed Web of Science ®Google Scholar
• Reiniger N, Lau K, McCalla D, Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse. Diabetes 2010;59:2043-54
   PubMed Web of Science ®Google Scholar
• Bolton WK, Cattran DC, Williams ME, Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004;24:32-40
   PubMed Web of Science ®Google Scholar
• La Selva M, Beltramo E, Pagnozzi F, Thiamine corrects delayed replication and decreases production of lactate and advanced glycation end-products in bovine retinal and human umbilical vein endothelial cells cultured under high glucose conditions. Diabetologia 1996;39:1263-8
   PubMed Web of Science ®Google Scholar
• Thornalley PJ. The potential role of thiamine (vitamin B1) in diabetic complications. Curr Diabetes Rev 2005;1:287-98
   PubMedGoogle Scholar
• Babaei-Jadidi R, Karachalias N, Ahmed N, Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 2003;52:2110-20
   PubMed Web of Science ®Google Scholar
• Abaterusso C, Gambaro G. The role of glycosaminoglycans and sulodexide in the treatment of diabetic nephropathy. Treat Endocrinol 2006;5:211-22
   PubMedGoogle Scholar
• Alkhalaf A, Klooster A, van Oeveren W, A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care 2010;33:1598-601
   PubMed Web of Science ®Google Scholar
• Nagaraj RH, Sarkar P, Mally A, Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal. Arch Biochem Biophys 2002;402:110-19
   PubMed Web of Science ®Google Scholar
• Degenhardt TP, Alderson NL, Arrington DD, Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002;61:939-50
   PubMed Web of Science ®Google Scholar
• Alderson NL, Chachich ME, Youssef NN, The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int 2003;63:2123-33
   PubMed Web of Science ®Google Scholar
• Williams ME, Bolton WK, Khalifah RG, Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol 2007;27:605-14
   PubMed Web of Science ®Google Scholar
• Cooper ME, Thallas V, Forbes J, The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation. Diabetologia 2000;43:660-4
   PubMed Web of Science ®Google Scholar
• Thallas-Bonke V, Lindschau C, Rizkalla B, Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway. Diabetes 2004;53:2921-30
   PubMed Web of Science ®Google Scholar
• Zieman SJ, Melenovsky V, Clattenburg L, Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens 2007;25:577-83
   PubMed Web of Science ®Google Scholar
• Twigg SM, Cooper ME. The time has come to target connective tissue growth factor in diabetic complications. Diabetologia 2004;47:965-8
   PubMed Web of Science ®Google Scholar
• Okada H, Kikuta T, Kobayashi T, Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis. J Am Soc Nephrol 2005;16:133-43
   PubMed Web of Science ®Google Scholar
• Oemar BS, Luscher TF. Connective tissue growth factor. Friend or foe? Arterioscler Thromb Vasc Biol 1997;17:1483-9
   PubMed Web of Science ®Google Scholar
• Grotendorst GR. Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev 1997;8:171-9
   PubMedGoogle Scholar
• Goldschmeding R, Aten J, Ito Y, Connective tissue growth factor: just another factor in renal fibrosis? Nephrol Dial Transplant 2000;15:296-9
   PubMed Web of Science ®Google Scholar
• Burns WC, Kantharidis P, Thomas MC. The role of tubular epithelial-mesenchymal transition in progressive kidney disease. Cells Tissues Organs 2007;185:222-31
   PubMed Web of Science ®Google Scholar
• Burns WC, Twigg SM, Forbes JM, Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol 2006;17:2484-94
   PubMed Web of Science ®Google Scholar
• Lassila M, Jandeleit-Dahm K, Seah KK, Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol 2005;16:363-73
   PubMed Web of Science ®Google Scholar
• Mokhtari D, Welsh N. Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes. Clin Sci (Lond) 2009;118:241-7
   PubMed Web of Science ®Google Scholar
• Mogyorosi A, Ziyadeh FN. What is the role of decorin in diabetic kidney disease? Nephrol Dial Transplant 1999;14:1078-81
   PubMed Web of Science ®Google Scholar
• Miric G, Dallemagne C, Endre Z, Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol 2001;133:687-94
   PubMed Web of Science ®Google Scholar
• RamachandraRao SP, Zhu Y, Ravasi T, Pirfenidone is renoprotective in diabetic kidney disease. J Am Soc Nephrol 2009;20:1765-75
   PubMed Web of Science ®Google Scholar
• Cho ME, Smith DC, Branton MH, Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2007;2:906-13
   PubMed Web of Science ®Google Scholar
• Tan SM, Zhang Y, Cox AJ, Tranilast attenuates the up-regulation of thioredoxin-interacting protein and oxidative stress in an experimental model of diabetic nephropathy. Nephrol Dial Transplant
   Web of Science ®Google Scholar
• Mifsud S, Kelly DJ, Qi W, Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy. Nephron Physiol 2003;95:83-91
   Google Scholar
• Soma J, Sugawara T, Huang YD, Tranilast slows the progression of advanced diabetic nephropathy. Nephron 2002;92:693-8
   PubMed Web of Science ®Google Scholar
• Soma J, Sato K, Saito H, Tsuchiya Y. Effect of tranilast in early-stage diabetic nephropathy. Nephrol Dial Transplant 2006;21:2795-9
   PubMed Web of Science ®Google Scholar
• Zammit SC, Cox AJ, Gow RM, Evaluation and optimization of antifibrotic activity of cinnamoyl anthranilates. Bioorg Med Chem Lett 2009;19:7003-6
   PubMed Web of Science ®Google Scholar
• Meier M, Park JK, Overheu D, Deletion of protein kinase C-beta isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocin-induced diabetic mouse model. Diabetes 2007;56:346-54
   PubMed Web of Science ®Google Scholar
• Koya D, Haneda M, Nakagawa H, Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 2000;14:439-47
   PubMed Web of Science ®Google Scholar
• Ishii H, Jirousek MR, Koya D, Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996;272:728-31
   PubMed Web of Science ®Google Scholar
• Tuttle KR, Bakris GL, Toto RD, The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005;28:2686-90
   PubMed Web of Science ®Google Scholar
• Tuttle KR, McGill JB, Haney DJ, Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease. Clin J Am Soc Nephrol 2007;2:631-6
   PubMed Web of Science ®Google Scholar
• Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008;57:1446-54
   PubMed Web of Science ®Google Scholar
• Chacko B, Reily C, Srivastava A, Prevention of diabetic nephropathy in Ins2+/-AkitaJ mice by the mitochondria-targeted therapy Mito Q. Biochem J 2010;432:9-19
   PubMed Web of Science ®Google Scholar
• Gorin Y, Block K, Hernandez J, Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J Biol Chem 2005;280:39616-26
   PubMed Web of Science ®Google Scholar
• Asaba K, Tojo A, Onozato ML, Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int 2005;67:1890-8
   PubMed Web of Science ®Google Scholar
• Lonn E, Yusuf S, Hoogwerf B, Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 2002;25:1919-27
   PubMed Web of Science ®Google Scholar
• Mann JF, Lonn EM, Yi Q, Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. Kidney Int 2004;65:1375-80
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Torita M, Yoshizawa M, Usuda R. Indication of vitamin E on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Metab 2001;27:611-12
   PubMed Web of Science ®Google Scholar
• Farvid MS, Jalali M, Siassi F, Hosseini M. Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes. Diabetes Care 2005;28:2458-64
   PubMed Web of Science ®Google Scholar
• Gaede P, Poulsen HE, Parving HH, Pedersen O. Double-blind, randomised study of the effect of combined treatment with vitamin C and E on albuminuria in Type 2 diabetic patients. Diabet Med 2001;18:756-60
   PubMed Web of Science ®Google Scholar
• Goicoechea M, de Vinuesa SG, Verdalles U, Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010;5:1388-93
   PubMed Web of Science ®Google Scholar
• Morcos M, Borcea V, Isermann B, Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study. Diabetes Res Clin Pract 2001;52:175-83
   PubMed Web of Science ®Google Scholar
• Zibadi S, Rohdewald PJ, Park D, Watson RR. Reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycnogenol supplementation. Nutr Res 2008;28:315-20
   PubMed Web of Science ®Google Scholar
• Kar P, Laight D, Rooprai HK, Effects of grape seed extract in type 2 diabetic subjects at high cardiovascular risk: a double blind randomized placebo controlled trial examining metabolic markers, vascular tone, inflammation, oxidative stress and insulin sensitivity. Diabet Med 2009;26:526-31
   PubMed Web of Science ®Google Scholar
• Kadhim HM, Ismail SH, Hussein KI, Effects of melatonin and zinc on lipid profile and renal function in type 2 diabetic patients poorly controlled with metformin. J Pineal Res 2006;41:189-93
   PubMed Web of Science ®Google Scholar
• DeRubertis FR, Craven PA, Melhem MF. Acceleration of diabetic renal injury in the superoxide dismutase knockout mouse: effects of tempol. Metabolism 2007;56:1256-64
   PubMed Web of Science ®Google Scholar
• Gealekman O, Brodsky SV, Zhang F, Endothelial dysfunction as a modifier of angiogenic response in Zucker diabetic fat rat: amelioration with Ebselen. Kidney Int 2004;66:2337-47
   PubMed Web of Science ®Google Scholar
• Pergola PE, Krauth M, Huff JW, Effect of bardoxolone methyl on kidney function in patients with T2D and stage 3b-4 CKD. Am J Nephrol 2011;33:469-76
   PubMed Web of Science ®Google Scholar
• Johnstone MT, Creager SJ, Scales KM, Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993;88:2510-16
   PubMed Web of Science ®Google Scholar
• Williams SB, Cusco JA, Roddy M-A, Impaired nitric oxide-mediated vasodilatation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1996;27:567-74
   PubMed Web of Science ®Google Scholar
• Gladwin MT. Deconstructing endothelial dysfunction: soluble guanylyl cyclase oxidation and the NO resistance syndrome. J Clin Invest 2006;116:2330-2
   PubMed Web of Science ®Google Scholar
• Liu S, Ma X, Gong M, Glucose down-regulation of cGMP-dependent protein kinase I expression in vascular smooth muscle cells involves NAD(P)H oxidase-derived reactive oxygen species. Free Radic Biol Med 2007;42:852-63
   PubMed Web of Science ®Google Scholar
• Kuno Y, Iyoda M, Shibata T, Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulin-dependent Otsuka Long-Evans Tokushima Fatty rats. Br J Pharmacol 2011;162:1389-400
   PubMed Web of Science ®Google Scholar
• Grover-Paez F, Villegas Rivera G, Guillen Ortiz R. Sildenafil citrate diminishes microalbuminuria and the percentage of A1c in male patients with type 2 diabetes. Diabetes Res Clin Pract 2007;78:136-40
   PubMed Web of Science ®Google Scholar
• Onozato ML, Tojo A, Goto A, Fujita T. Effect of combination therapy with dipyridamole and quinapril in diabetic nephropathy. Diabetes Res Clin Pract 2003;59:83-92
   PubMed Web of Science ®Google Scholar
• Aizawa T, Suzuki S, Asawa T, Dipyridamole reduces urinary albumin excretion in diabetic patients with normo- or microalbuminuria. Clin Nephrol 1990;33:130-5
   PubMed Web of Science ®Google Scholar
• Gambaro G, Cavazzana AO, Luzi P, Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int 1992;42:285-91
   PubMed Web of Science ®Google Scholar
• Achour A, Kacem M, Dibej K, One year course of oral sulodexide in the management of diabetic nephropathy. J Nephrol 2005;18:568-74
   PubMed Web of Science ®Google Scholar
• van der Pijl JW, van der Woude FJ, Geelhoed-Duijvestijn PH, Danaparoid sodium lowers proteinuria in diabetic nephropathy. J Am Soc Nephrol 1997;8:456-62
   PubMed Web of Science ®Google Scholar
• Gambaro G, Kinalska I, Oksa A, Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol 2002;13:1615-25
   PubMed Web of Science ®Google Scholar
• Sulikowska B, Olejniczak H, Muszynska M, Effect of sulodexide on albuminuria, NAG excretion and glomerular filtration response to dopamine in diabetic patients. Am J Nephrol 2006;26:621-8
   PubMed Web of Science ®Google Scholar
• Blouza S, Dakhli S, Abid H, Efficacy of low-dose oral sulodexide in the management of diabetic nephropathy. J Nephrol 2010;23:415-24
   PubMed Web of Science ®Google Scholar
• Navarro JF, Mora C, Muros M, Garcia J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J Am Soc Nephrol 2005;16:2119-26
   PubMed Web of Science ®Google Scholar
• Aminorroaya A, Janghorbani M, Rezvanian H, Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus. Nephron Clin Pract 2005;99:c73-7
   PubMed Web of Science ®Google Scholar
• Moriwaki Y, Inokuchi T, Yamamoto A, Effect of TNF-alpha inhibition on urinary albumin excretion in experimental diabetic rats. Acta Diabetol 2007;44:215-18
   PubMed Web of Science ®Google Scholar
• DiPetrillo K, Coutermarsh B, Gesek FA. Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. Am J Physiol Renal Physiol 2003;284:F113-21
   PubMed Web of Science ®Google Scholar
• Neuhofer W, Pittrow D. Role of endothelin and endothelin receptor antagonists in renal disease. Eur J Clin Invest 2006;36(Suppl 3):78-88
   PubMed Web of Science ®Google Scholar
• Hocher B, Thone-Reineke C, Rohmeiss P, Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 1997;99:1380-9
   PubMed Web of Science ®Google Scholar
• Nakamura T, Ebihara I, Fukui M, Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli. Diabetes 1995;44:895-9
   PubMed Web of Science ®Google Scholar
• Dhein S, Hochreuther S, Aus Dem Spring C, Long-term effects of the endothelin(A) receptor antagonist LU 135252 and the angiotensin-converting enzyme inhibitor trandolapril on diabetic angiopathy and nephropathy in a chronic type I diabetes mellitus rat model. J Pharmacol Exp Ther 2000;293:351-9
   PubMed Web of Science ®Google Scholar
• Hocher B, Schwarz A, Reinbacher D, Effects of endothelin receptor antagonists on the progression of diabetic nephropathy. Nephron 2001;87:161-9
   PubMed Web of Science ®Google Scholar
• Sasser JM, Sullivan JC, Hobbs JL, Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol 2007;18:143-54
   PubMed Web of Science ®Google Scholar
• Mann JF, Green D, Jamerson K, Avosentan for overt diabetic nephropathy. J Am Soc Nephrol2010;21:655-64
   Google Scholar
• Wenzel RR, Littke T, Kuranoff S, Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 2009;20:655-64
   PubMed Web of Science ®Google Scholar
• Hernandez Prada JA, Ferreira AJ, Katovich MJ, Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension 2008;51:1312-17
   PubMed Web of Science ®Google Scholar